[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].
Identifieur interne : 000044 ( Main/Exploration ); précédent : 000043; suivant : 000045[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].
Auteurs : Pascale Grosclaude [France] ; David Azria [France] ; Rosine Guimbaud [France] ; Séverine Thibault [France] ; Laetitia Daubisse-Marliac [France] ; Guillaume Cartron [France] ; Marie-José Renaudie [France] ; Pierre-Adrien Dalbies [France] ; Jean-Pierre Delord [France] ; Eric Bauvin [France]Source :
- Bulletin du cancer [ 1769-6917 ]
Descripteurs français
- KwdFr :
- Adhésion aux directives (MeSH), Archives administratives hospitalières (MeSH), Betacoronavirus (MeSH), Comités du personnel de santé (organisation et administration), Comités du personnel de santé (statistiques et données numériques), Communication interdisciplinaire (MeSH), Composition d'un comité (MeSH), Engagement dans le travail (MeSH), France (épidémiologie), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Infections à coronavirus (MeSH), Oncologie médicale (organisation et administration), Pandémies (MeSH), Pneumopathie virale (MeSH), Rendement (MeSH), Tumeurs (thérapie), Tumeurs (épidémiologie), Équipe soignante (organisation et administration).
- MESH :
- organisation et administration : Comités du personnel de santé, Oncologie médicale, Équipe soignante.
- statistiques et données numériques : Comités du personnel de santé.
- thérapie : Tumeurs.
- épidémiologie : France, Tumeurs.
- Adhésion aux directives, Archives administratives hospitalières, Betacoronavirus, Communication interdisciplinaire, Composition d'un comité, Engagement dans le travail, Guides de bonnes pratiques cliniques comme sujet, Humains, Infections à coronavirus, Pandémies, Pneumopathie virale, Rendement.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), Committee Membership (MeSH), Coronavirus Infections (MeSH), Efficiency (MeSH), France (epidemiology), Guideline Adherence (MeSH), Hospital Records (MeSH), Humans (MeSH), Interdisciplinary Communication (MeSH), Medical Oncology (organization & administration), Neoplasms (epidemiology), Neoplasms (therapy), Pandemics (MeSH), Patient Care Team (organization & administration), Pneumonia, Viral (MeSH), Practice Guidelines as Topic (MeSH), Professional Staff Committees (organization & administration), Professional Staff Committees (statistics & numerical data), Work Engagement (MeSH).
- MESH :
- geographic , epidemiology : France.
- epidemiology : Neoplasms.
- organization & administration : Medical Oncology, Patient Care Team, Professional Staff Committees.
- statistics & numerical data : Professional Staff Committees.
- therapy : Neoplasms.
- Betacoronavirus, Committee Membership, Coronavirus Infections, Efficiency, Guideline Adherence, Hospital Records, Humans, Interdisciplinary Communication, Pandemics, Pneumonia, Viral, Practice Guidelines as Topic, Work Engagement.
Abstract
This work examines the impact of the SARS-CoV2 epidemic and the organizational recommendations that have been issued since March 16 on tumor boards (TB) activity. The tumor board activity was measured from tumor board sheets extracted from the oncologic electronic file between January 7, 2019 and April 24, 2020. The pre-containment activity was compared to the activity of the containment periods but also to the equivalent periods in 2019. The number of meetings held, the average number of files reviewed per meeting including first presentations and the average number of physicians' attendance were the evaluation criteria. The study covered 191 TB that held 3943 multidisciplinary team meetings (MTM) and reviewed 72,070 files (including 30,127 first submissions). There was a moderate decrease of 8 % in the number of meetings after March 16, 2020. The number of files examined decreased by 23 % in the following month and even more by 33 % in the third period. The physicians' number who attended MTM also decreased by 25 %. The negative impact was higher in the Mediterranean part of the region. This first study of tumor board activity, covering a large region but little affected by the pandemic, shows that its impact on the participation to the MTM has been moderate. In addition, tumor boards have followed the recommendations for optimizing quorum. However, the decrease in average MTM activity, particularly for first submissions, suggests a potential delay in patient management. Complementary qualitative and quantitative works are warranted to estimate the real impact on carcinologic outcomes.
DOI: 10.1016/j.bulcan.2020.05.001
PubMed: 32425210
PubMed Central: PMC7231733
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].</title><author><name sortKey="Grosclaude, Pascale" sort="Grosclaude, Pascale" uniqKey="Grosclaude P" first="Pascale" last="Grosclaude">Pascale Grosclaude</name><affiliation wicri:level="3"><nlm:affiliation>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France. Electronic address: pascale.grosclaude@inserm.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Azria, David" sort="Azria, David" uniqKey="Azria D" first="David" last="Azria">David Azria</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Guimbaud, Rosine" sort="Guimbaud, Rosine" uniqKey="Guimbaud R" first="Rosine" last="Guimbaud">Rosine Guimbaud</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Thibault, Severine" sort="Thibault, Severine" uniqKey="Thibault S" first="Séverine" last="Thibault">Séverine Thibault</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Daubisse Marliac, Laetitia" sort="Daubisse Marliac, Laetitia" uniqKey="Daubisse Marliac L" first="Laetitia" last="Daubisse-Marliac">Laetitia Daubisse-Marliac</name><affiliation wicri:level="3"><nlm:affiliation>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Renaudie, Marie Jose" sort="Renaudie, Marie Jose" uniqKey="Renaudie M" first="Marie-José" last="Renaudie">Marie-José Renaudie</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Dalbies, Pierre Adrien" sort="Dalbies, Pierre Adrien" uniqKey="Dalbies P" first="Pierre-Adrien" last="Dalbies">Pierre-Adrien Dalbies</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Delord, Jean Pierre" sort="Delord, Jean Pierre" uniqKey="Delord J" first="Jean-Pierre" last="Delord">Jean-Pierre Delord</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Bauvin, Eric" sort="Bauvin, Eric" uniqKey="Bauvin E" first="Eric" last="Bauvin">Eric Bauvin</name><affiliation wicri:level="3"><nlm:affiliation>UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jul - Aug</date><idno type="RBID">pubmed:32425210</idno><idno type="pmid">32425210</idno><idno type="doi">10.1016/j.bulcan.2020.05.001</idno><idno type="pmc">PMC7231733</idno><idno type="wicri:Area/Main/Corpus">001223</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001223</idno><idno type="wicri:Area/Main/Curation">001223</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001223</idno><idno type="wicri:Area/Main/Exploration">001223</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].</title><author><name sortKey="Grosclaude, Pascale" sort="Grosclaude, Pascale" uniqKey="Grosclaude P" first="Pascale" last="Grosclaude">Pascale Grosclaude</name><affiliation wicri:level="3"><nlm:affiliation>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France. Electronic address: pascale.grosclaude@inserm.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Azria, David" sort="Azria, David" uniqKey="Azria D" first="David" last="Azria">David Azria</name><affiliation wicri:level="3"><nlm:affiliation>Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Guimbaud, Rosine" sort="Guimbaud, Rosine" uniqKey="Guimbaud R" first="Rosine" last="Guimbaud">Rosine Guimbaud</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Thibault, Severine" sort="Thibault, Severine" uniqKey="Thibault S" first="Séverine" last="Thibault">Séverine Thibault</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Daubisse Marliac, Laetitia" sort="Daubisse Marliac, Laetitia" uniqKey="Daubisse Marliac L" first="Laetitia" last="Daubisse-Marliac">Laetitia Daubisse-Marliac</name><affiliation wicri:level="3"><nlm:affiliation>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Renaudie, Marie Jose" sort="Renaudie, Marie Jose" uniqKey="Renaudie M" first="Marie-José" last="Renaudie">Marie-José Renaudie</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Dalbies, Pierre Adrien" sort="Dalbies, Pierre Adrien" uniqKey="Dalbies P" first="Pierre-Adrien" last="Dalbies">Pierre-Adrien Dalbies</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Delord, Jean Pierre" sort="Delord, Jean Pierre" uniqKey="Delord J" first="Jean-Pierre" last="Delord">Jean-Pierre Delord</name><affiliation wicri:level="3"><nlm:affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Bauvin, Eric" sort="Bauvin, Eric" uniqKey="Bauvin E" first="Eric" last="Bauvin">Eric Bauvin</name><affiliation wicri:level="3"><nlm:affiliation>UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author></analytic><series><title level="j">Bulletin du cancer</title><idno type="eISSN">1769-6917</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>Committee Membership (MeSH)</term><term>Coronavirus Infections (MeSH)</term><term>Efficiency (MeSH)</term><term>France (epidemiology)</term><term>Guideline Adherence (MeSH)</term><term>Hospital Records (MeSH)</term><term>Humans (MeSH)</term><term>Interdisciplinary Communication (MeSH)</term><term>Medical Oncology (organization & administration)</term><term>Neoplasms (epidemiology)</term><term>Neoplasms (therapy)</term><term>Pandemics (MeSH)</term><term>Patient Care Team (organization & administration)</term><term>Pneumonia, Viral (MeSH)</term><term>Practice Guidelines as Topic (MeSH)</term><term>Professional Staff Committees (organization & administration)</term><term>Professional Staff Committees (statistics & numerical data)</term><term>Work Engagement (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adhésion aux directives (MeSH)</term><term>Archives administratives hospitalières (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Comités du personnel de santé (organisation et administration)</term><term>Comités du personnel de santé (statistiques et données numériques)</term><term>Communication interdisciplinaire (MeSH)</term><term>Composition d'un comité (MeSH)</term><term>Engagement dans le travail (MeSH)</term><term>France (épidémiologie)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (MeSH)</term><term>Oncologie médicale (organisation et administration)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (MeSH)</term><term>Rendement (MeSH)</term><term>Tumeurs (thérapie)</term><term>Tumeurs (épidémiologie)</term><term>Équipe soignante (organisation et administration)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Comités du personnel de santé</term><term>Oncologie médicale</term><term>Équipe soignante</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Medical Oncology</term><term>Patient Care Team</term><term>Professional Staff Committees</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Professional Staff Committees</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Comités du personnel de santé</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>France</term><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Committee Membership</term><term>Coronavirus Infections</term><term>Efficiency</term><term>Guideline Adherence</term><term>Hospital Records</term><term>Humans</term><term>Interdisciplinary Communication</term><term>Pandemics</term><term>Pneumonia, Viral</term><term>Practice Guidelines as Topic</term><term>Work Engagement</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adhésion aux directives</term><term>Archives administratives hospitalières</term><term>Betacoronavirus</term><term>Communication interdisciplinaire</term><term>Composition d'un comité</term><term>Engagement dans le travail</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term><term>Rendement</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This work examines the impact of the SARS-CoV2 epidemic and the organizational recommendations that have been issued since March 16 on tumor boards (TB) activity. The tumor board activity was measured from tumor board sheets extracted from the oncologic electronic file between January 7, 2019 and April 24, 2020. The pre-containment activity was compared to the activity of the containment periods but also to the equivalent periods in 2019. The number of meetings held, the average number of files reviewed per meeting including first presentations and the average number of physicians' attendance were the evaluation criteria. The study covered 191 TB that held 3943 multidisciplinary team meetings (MTM) and reviewed 72,070 files (including 30,127 first submissions). There was a moderate decrease of 8 % in the number of meetings after March 16, 2020. The number of files examined decreased by 23 % in the following month and even more by 33 % in the third period. The physicians' number who attended MTM also decreased by 25 %. The negative impact was higher in the Mediterranean part of the region. This first study of tumor board activity, covering a large region but little affected by the pandemic, shows that its impact on the participation to the MTM has been moderate. In addition, tumor boards have followed the recommendations for optimizing quorum. However, the decrease in average MTM activity, particularly for first submissions, suggests a potential delay in patient management. Complementary qualitative and quantitative works are warranted to estimate the real impact on carcinologic outcomes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32425210</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1769-6917</ISSN><JournalIssue CitedMedium="Internet"><Volume>107</Volume><Issue>7-8</Issue><PubDate><MedlineDate>2020 Jul - Aug</MedlineDate></PubDate></JournalIssue><Title>Bulletin du cancer</Title><ISOAbbreviation>Bull Cancer</ISOAbbreviation></Journal><ArticleTitle>[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].</ArticleTitle><Pagination><MedlinePgn>730-737</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0007-4551(20)30233-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bulcan.2020.05.001</ELocationID><Abstract><AbstractText>This work examines the impact of the SARS-CoV2 epidemic and the organizational recommendations that have been issued since March 16 on tumor boards (TB) activity. The tumor board activity was measured from tumor board sheets extracted from the oncologic electronic file between January 7, 2019 and April 24, 2020. The pre-containment activity was compared to the activity of the containment periods but also to the equivalent periods in 2019. The number of meetings held, the average number of files reviewed per meeting including first presentations and the average number of physicians' attendance were the evaluation criteria. The study covered 191 TB that held 3943 multidisciplinary team meetings (MTM) and reviewed 72,070 files (including 30,127 first submissions). There was a moderate decrease of 8 % in the number of meetings after March 16, 2020. The number of files examined decreased by 23 % in the following month and even more by 33 % in the third period. The physicians' number who attended MTM also decreased by 25 %. The negative impact was higher in the Mediterranean part of the region. This first study of tumor board activity, covering a large region but little affected by the pandemic, shows that its impact on the participation to the MTM has been moderate. In addition, tumor boards have followed the recommendations for optimizing quorum. However, the decrease in average MTM activity, particularly for first submissions, suggests a potential delay in patient management. Complementary qualitative and quantitative works are warranted to estimate the real impact on carcinologic outcomes.</AbstractText><CopyrightInformation>Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grosclaude</LastName><ForeName>Pascale</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France. Electronic address: pascale.grosclaude@inserm.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azria</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guimbaud</LastName><ForeName>Rosine</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thibault</LastName><ForeName>Séverine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daubisse-Marliac</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cartron</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Renaudie</LastName><ForeName>Marie-José</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalbies</LastName><ForeName>Pierre-Adrien</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delord</LastName><ForeName>Jean-Pierre</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauvin</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Impact du SARS-CoV2 sur la structuration de la prise en charge du cancer : exemple de la tenue des RCP de cancérologie en Occitanie.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Bull Cancer</MedlineTA><NlmUniqueID>0072416</NlmUniqueID><ISSNLinking>0007-4551</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032802" MajorTopicYN="N">Committee Membership</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004526" MajorTopicYN="N">Efficiency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006753" MajorTopicYN="N">Hospital Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033183" MajorTopicYN="Y">Interdisciplinary Communication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="Y">Patient Care Team</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011367" MajorTopicYN="N">Professional Staff Committees</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization & administration</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074824" MajorTopicYN="N">Work Engagement</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cancérologie</Keyword><Keyword MajorTopicYN="N">Multidisciplinary team meeting</Keyword><Keyword MajorTopicYN="N">Oncology</Keyword><Keyword MajorTopicYN="N">Quality of Care</Keyword><Keyword MajorTopicYN="N">Qualité de la prise en charge</Keyword><Keyword MajorTopicYN="N">Réunion de concertation pluridisciplinaire</Keyword><Keyword MajorTopicYN="N">SARS-CoV2</Keyword><Keyword MajorTopicYN="N">Tumor board</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32425210</ArticleId><ArticleId IdType="doi">10.1016/j.bulcan.2020.05.001</ArticleId><ArticleId IdType="pii">S0007-4551(20)30233-2</ArticleId><ArticleId IdType="pmc">PMC7231733</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Oncol. 2020 May;21(5):619-621</Citation><ArticleIdList><ArticleId IdType="pubmed">32220659</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Languedoc-Roussillon</li><li>Midi-Pyrénées</li><li>Occitanie (région administrative)</li></region><settlement><li>Montpellier</li><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Grosclaude, Pascale" sort="Grosclaude, Pascale" uniqKey="Grosclaude P" first="Pascale" last="Grosclaude">Pascale Grosclaude</name></region><name sortKey="Azria, David" sort="Azria, David" uniqKey="Azria D" first="David" last="Azria">David Azria</name><name sortKey="Bauvin, Eric" sort="Bauvin, Eric" uniqKey="Bauvin E" first="Eric" last="Bauvin">Eric Bauvin</name><name sortKey="Cartron, Guillaume" sort="Cartron, Guillaume" uniqKey="Cartron G" first="Guillaume" last="Cartron">Guillaume Cartron</name><name sortKey="Dalbies, Pierre Adrien" sort="Dalbies, Pierre Adrien" uniqKey="Dalbies P" first="Pierre-Adrien" last="Dalbies">Pierre-Adrien Dalbies</name><name sortKey="Daubisse Marliac, Laetitia" sort="Daubisse Marliac, Laetitia" uniqKey="Daubisse Marliac L" first="Laetitia" last="Daubisse-Marliac">Laetitia Daubisse-Marliac</name><name sortKey="Delord, Jean Pierre" sort="Delord, Jean Pierre" uniqKey="Delord J" first="Jean-Pierre" last="Delord">Jean-Pierre Delord</name><name sortKey="Guimbaud, Rosine" sort="Guimbaud, Rosine" uniqKey="Guimbaud R" first="Rosine" last="Guimbaud">Rosine Guimbaud</name><name sortKey="Renaudie, Marie Jose" sort="Renaudie, Marie Jose" uniqKey="Renaudie M" first="Marie-José" last="Renaudie">Marie-José Renaudie</name><name sortKey="Thibault, Severine" sort="Thibault, Severine" uniqKey="Thibault S" first="Séverine" last="Thibault">Séverine Thibault</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000044 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000044 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32425210
|texte= [COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32425210" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |